JP2017535555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535555A5 JP2017535555A5 JP2017526523A JP2017526523A JP2017535555A5 JP 2017535555 A5 JP2017535555 A5 JP 2017535555A5 JP 2017526523 A JP2017526523 A JP 2017526523A JP 2017526523 A JP2017526523 A JP 2017526523A JP 2017535555 A5 JP2017535555 A5 JP 2017535555A5
- Authority
- JP
- Japan
- Prior art keywords
- treprostinil
- dcm
- dmf
- dioxane
- coupling reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 22
- 229960005032 Treprostinil Drugs 0.000 claims 12
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 10
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 230000001808 coupling Effects 0.000 claims 8
- 238000010168 coupling process Methods 0.000 claims 8
- 238000005859 coupling reaction Methods 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000003377 acid catalyst Substances 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 claims 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 2
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical group F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000532 dioxanyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrugs Drugs 0.000 claims 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- FKBFHOSFPRWJNV-UHFFFAOYSA-N [dimethylamino-(3-oxidotriazolo[4,5-b]pyridin-3-ium-1-yl)methylidene]-dimethylazanium;hexafluorophosphate Chemical group F[P-](F)(F)(F)(F)F.C1=CC=C2[N+](=C(N(C)C)N(C)C)N=[N+]([O-])C2=N1 FKBFHOSFPRWJNV-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910021389 graphene Inorganic materials 0.000 claims 1
- -1 heteropolyacids Substances 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims 1
- 239000011970 polystyrene sulfonate Substances 0.000 claims 1
- 229960002796 polystyrene sulfonate Drugs 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- 239000010457 zeolite Substances 0.000 claims 1
Claims (19)
- 前記カップリング試薬が1−[ビス(ジメチルアミノ)メチレン]−1H−1,2,3−トリアゾロ[4,5−b]ピリジニウム3−オキシドヘキサフルオロリン酸(HATU)である、請求項1に記載の方法。
- 前記カップリング試薬がベンゾトリアゾール−1−イルオキシトリピロリジノホスホニウムヘキサフルオロリン酸塩(PyBOP)である、請求項1に記載の方法。
- 前記カップリング試薬が炭酸N,N’−ジイソスクシンイミジル(DSC)である、請求項1に記載の方法。
- 前記カップリング試薬がN,N’−ジシクロヘキシルカルボジイミド(DCC)、N,N’−ジイソプロピルカルボジイミド(DIC)またはN−(3−ジメチルアミノプロピル)−N’−エチルカルボジイミド塩酸塩(EDC)である、請求項1に記載の方法。
- トレプロスチニルおよび前記カップリング試薬をある期間混合した後、式R 1 −NH 2 の化合物がトレプロスチニルおよび前記カップリング試薬に添加される、請求項1〜5のいずれか一項に記載の方法。
- 前記期間が約30分間〜約96時間、約30分間〜約72時間、約30分間〜約48時間、約30分間〜約24時間または約30分間〜約150分間である、請求項6に記載の方法。
- トレプロスチニルが溶媒に溶解されている、請求項1〜7のいずれか一項に記載の方法。
- 前記溶媒がジオキサンを含む、請求項8に記載の方法。
- 前記溶媒がアセトニトリル(MeCN)、N,N’−ジメチルホルムアミド(DMF)、ジクロロメタン(DCM)またはこれらの組合せを含む、請求項8に記載の方法。
- 前記溶媒が、ジオキサン(2mL/100μmol トレプロスチニル)、ジオキサン(1mL/100μmol トレプロスチニル)、DMF、DCM、MeCN、ジオキサン:MeCN(1:1)、DMF/DCM、10%DMF/DCMまたは20%DMF/DCMを含む、請求項8に記載の方法。
- トレプロスチニルが、前記酸触媒と混合される前に溶媒に溶解される、請求項12に記載の方法。
- 前記溶媒がジオキサンを含む、請求項13に記載の方法。
- 前記溶媒が、アセトニトリル(MeCN)、N,N’−ジメチルホルムアミド(DMF)、ジクロロメタン(DCM)またはこれらの組合せを含む、請求項13に記載の方法。
- 前記溶媒が、ジオキサン(2mL/100μmol トレプロスチニル)、ジオキサン(1mL/100μmol トレプロスチニル)、DMF、DCM、MeCN、ジオキサン:MeCN(1:1)、DMF/DCM、10%DMF/DCMまたは20%DMF/DCMを含む、請求項13に記載の方法。
- 前記酸触媒が固体である、請求項12〜16のいずれか一項に記載の方法。
- 前記固体が固体樹脂である、請求項17に記載の方法。
- 前記酸触媒が、硫酸、スルホン酸、フッ化水素酸、リン酸、トルエンスルホン酸、ポリスチレンスルホン酸塩、ヘテロポリ酸、ゼオライト、金属酸化物、グラフェンオキシジェンまたはこれらの組合せを含む、請求項12〜18のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462081515P | 2014-11-18 | 2014-11-18 | |
US62/081,515 | 2014-11-18 | ||
PCT/US2015/061427 WO2016081658A1 (en) | 2014-11-18 | 2015-11-18 | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017535555A JP2017535555A (ja) | 2017-11-30 |
JP2017535555A5 true JP2017535555A5 (ja) | 2018-12-27 |
JP6866043B2 JP6866043B2 (ja) | 2021-04-28 |
Family
ID=56014536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017526523A Active JP6866043B2 (ja) | 2014-11-18 | 2015-11-18 | トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US10343979B2 (ja) |
EP (2) | EP3221291B1 (ja) |
JP (1) | JP6866043B2 (ja) |
AU (1) | AU2015349969B2 (ja) |
CA (1) | CA2967385C (ja) |
ES (1) | ES2873873T3 (ja) |
HK (1) | HK1244783A1 (ja) |
WO (1) | WO2016081658A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2927844T3 (es) | 2013-01-11 | 2022-11-11 | Corsair Pharma Inc | Profármacos de treprostinil |
US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
EA031604B1 (ru) | 2013-10-25 | 2019-01-31 | Инсмед Инкорпорейтед | Трепростинильные соединения, композиции и способы их использования |
CA2967385C (en) | 2014-11-18 | 2023-05-16 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
WO2017223400A1 (en) * | 2016-06-24 | 2017-12-28 | Insmed Incorporated | Prostacyclin compounds and compositions for treating sarcoidosis |
CA3038276A1 (en) | 2016-09-26 | 2018-03-29 | United Therapeutics Corporation | Treprostinil prodrugs |
KR20220002600A (ko) | 2019-04-29 | 2022-01-06 | 인스메드 인코포레이티드 | 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법 |
CN114616225A (zh) | 2019-08-23 | 2022-06-10 | 联合治疗公司 | 曲前列环素前药 |
US10781160B1 (en) * | 2019-10-04 | 2020-09-22 | Chirogate International Inc. | Hexadecyl Treprostinil crystals and methods for preparation thereof |
AU2021255621A1 (en) | 2020-04-17 | 2022-10-20 | United Therapeutics Corporation | Treprostinil for use in the treatment of intersitial lung disease |
JP2023529828A (ja) | 2020-06-09 | 2023-07-12 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルのフマリルジケトピペリジンプロドラッグ |
IL303668A (en) | 2020-12-14 | 2023-08-01 | United Therapeutics Corp | Stable treprostinil prodrugs and their uses for the treatment of diseases |
WO2022187352A1 (en) | 2021-03-03 | 2022-09-09 | United Therapeutics Corporation | A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp) |
US20230263807A1 (en) | 2022-02-08 | 2023-08-24 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2947526A1 (de) | 1978-11-29 | 1980-06-12 | Ono Pharmaceutical Co | Prostacyclin-analoge |
US4668814A (en) | 1984-03-08 | 1987-05-26 | The Upjohn Company | Interphenylene carbacyclin derivatives |
JPS61289034A (ja) | 1985-06-17 | 1986-12-19 | Teijin Ltd | イソカルバサイクリン類脂肪乳剤 |
US4837342A (en) | 1986-02-28 | 1989-06-06 | Sagami Chemical Research Center | Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient |
GB8814438D0 (en) | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
GB9011588D0 (en) | 1990-05-24 | 1990-07-11 | Wellcome Found | Prostaglandin analogues for use in medicine |
US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
CA2056039A1 (en) | 1991-01-22 | 1992-07-23 | Philip L. Fuchs | Carbacyclin analogs |
US5190972A (en) | 1992-01-27 | 1993-03-02 | The University Of Melbourne | Method of combatting cyclosporine organ toxicity with prostaglandin analogs |
CA2091152C (en) | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
US6441245B1 (en) | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
KR100638684B1 (ko) | 1997-11-14 | 2006-10-27 | 유나이티드 세러퓨틱스 코오포레이션 | 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도 |
AU742250B2 (en) | 1997-12-26 | 2001-12-20 | Astellas Pharma Inc. | Sustained release medicinal compositions |
EP1100464A1 (en) | 1998-07-31 | 2001-05-23 | Korea Institute Of Science And Technology | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier |
US6265495B1 (en) * | 1998-09-22 | 2001-07-24 | Nippon Shokubai Co., Ltd. | Method for production of esterified product |
US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
AU4327300A (en) | 1999-03-31 | 2000-10-16 | United Therapeutics Corporation | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension |
US6242482B1 (en) | 2000-06-05 | 2001-06-05 | United Therapeutics Corporation | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
US6306435B1 (en) | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
WO2003000236A1 (en) | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc | Particles with improved solubilization capacity |
US20030108512A1 (en) | 2001-12-10 | 2003-06-12 | Robert Shorr | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer |
US6803386B2 (en) | 2002-01-16 | 2004-10-12 | United Therapeutics Corporation | Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer |
US20040156816A1 (en) | 2002-08-06 | 2004-08-12 | David Anderson | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
US20050244503A1 (en) | 2003-05-19 | 2005-11-03 | Rabinow Barrett E | Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents |
ATE341312T1 (de) | 2003-05-20 | 2006-10-15 | Ethypharm Sa | Orale pharmazeutische zusammensetzung mit verzögerter freisetzung |
ES2622471T5 (es) * | 2003-05-22 | 2020-07-23 | United Therapeutics Corp | Compuestos y procedimientos para la administración de análogos de prostaciclina |
WO2005058329A1 (en) | 2003-12-16 | 2005-06-30 | United Therapeutics Corporation | Use of treprostinil to improve kidney functions |
US8765813B2 (en) | 2003-12-16 | 2014-07-01 | United Therapeutics Corporation | Use of treprostinil to treat and prevent ischemic lesions |
JP2007532663A (ja) | 2004-04-12 | 2007-11-15 | ユナイテッド セラピューティクス インコーポレイテッド | ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用 |
GB0416328D0 (en) | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
US20060147520A1 (en) | 2004-07-26 | 2006-07-06 | Curtis Ruegg | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
EP1806148A4 (en) | 2004-10-22 | 2009-12-02 | Ono Pharmaceutical Co | THERAPEUTIC PREPARATION FOR INHALATION |
EP1973523A2 (en) | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
CA2654492C (en) | 2006-05-15 | 2017-06-27 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
US20090036465A1 (en) | 2006-10-18 | 2009-02-05 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
WO2008098196A1 (en) | 2007-02-09 | 2008-08-14 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
WO2008124639A2 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
ES2728785T3 (es) | 2007-09-07 | 2019-10-28 | United Therapeutics Corp | Soluciones tampón con actividad bactericida selectiva contra las bacterias gramnegativas y métodos para usarlas |
KR101898407B1 (ko) | 2007-12-17 | 2018-09-12 | 유나이티드 세러퓨틱스 코오포레이션 | 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법 |
WO2009137066A1 (en) | 2008-05-08 | 2009-11-12 | United Therapeutics Corporation | Treprostinil monohydrate |
WO2009152160A1 (en) | 2008-06-10 | 2009-12-17 | Gilead Sciences, Inc. | Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension |
WO2009158010A1 (en) | 2008-06-27 | 2009-12-30 | Concert Pharmaceuticals, Inc. | Prostacyclin analogs |
WO2010039531A1 (en) | 2008-09-23 | 2010-04-08 | Resolvyx Pharmaceuticals, Inc. | Therapeutic compounds |
WO2010036798A1 (en) | 2008-09-25 | 2010-04-01 | Aradigm Corporation | Deep lung pulmonary delivery of treprostinil |
MX2011008647A (es) | 2009-02-20 | 2011-10-28 | Micro Labs Ltd | Producto de prostaglandina de almacenamiento estable. |
KR101544246B1 (ko) | 2009-05-07 | 2015-08-12 | 유나이티드 세러퓨틱스 코오포레이션 | 프로스타시클린 유사체의 고체 제제 |
JP6087147B2 (ja) | 2009-06-22 | 2017-03-01 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニーJohnson Matthey Public Limited Company | プロスタグランジンの精製方法 |
US20120270934A1 (en) | 2009-07-03 | 2012-10-25 | Concert Pharmaceuticals, Inc. | Prostacyclin derivatives |
JP5877787B2 (ja) | 2009-08-07 | 2016-03-08 | サイファーム ソシエテ ア レスポンサビリテ リミテSciPharmS.a r.l. | 嚢胞性線維症の治療のための組成物 |
US20120232034A1 (en) | 2009-08-21 | 2012-09-13 | Henk-Andre Kroon | Vesicular formulations |
CN101669904B (zh) | 2009-09-29 | 2011-06-22 | 北京中海康医药科技发展有限公司 | 一种依前列醇脂质纳米粒及制备方法 |
DK2525830T3 (en) | 2010-01-22 | 2016-08-15 | Ascendis Pharma As | DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES |
WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
KR20150027846A (ko) | 2010-03-15 | 2015-03-12 | 유나이티드 세러퓨틱스 코오포레이션 | 폐고혈압의 치료 |
ES2658139T3 (es) | 2010-06-03 | 2018-03-08 | United Therapeutics Corporation | Producción de treprostinil |
EP2582235A4 (en) | 2010-06-15 | 2014-04-30 | United Therapeutics Corp | ORAL TREATMENT OF DIGITAL ISCHEMIC LESIONS |
US20120010159A1 (en) | 2010-07-09 | 2012-01-12 | United Therapeutics Corporation | Combination therapies with cox-2 inhibitors and treprostinil |
CA2710726C (en) | 2010-07-22 | 2016-02-23 | Alphora Research Inc. | Synthesis of treprostinil and intermediates useful therein |
WO2012107364A1 (en) | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
JP5780775B2 (ja) | 2011-02-18 | 2015-09-16 | 株式会社Lttバイオファーマ | プロスタグランジンi2誘導体を含有するナノ粒子 |
EP2681204B1 (en) | 2011-03-02 | 2016-04-27 | United Therapeutics Corporation | Synthesis of intermediate for treprostinil production |
ES2832330T3 (es) | 2011-03-14 | 2021-06-10 | Univ Hokkaido Nat Univ Corp | Vector para administración pulmonar, agente inductor y usos |
EP2741778A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
US20140296257A1 (en) | 2011-08-12 | 2014-10-02 | Ascendis Pharma A/S | High-Loading Water-Soluable Carrier-Linked Prodrugs |
CN103874480A (zh) | 2011-08-12 | 2014-06-18 | 阿森迪斯药物股份有限公司 | 前列环素的缓释组合物 |
MX349950B (es) | 2011-08-12 | 2017-08-22 | Ascendis Pharma As | Profarmacos de treprostinil enlazados a un portador. |
EP3643306A3 (en) | 2011-08-12 | 2020-08-26 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
US8524939B2 (en) | 2011-08-24 | 2013-09-03 | Chirogate International Inc. | Intermediates for the synthesis of benzindene prostaglandins and preparations thereof |
US9387214B2 (en) | 2012-01-13 | 2016-07-12 | United Therapeutics Corporation | Method of identifying therapies for pulmonary hypertension |
DK2674413T3 (en) | 2012-06-15 | 2017-09-18 | Scipharm Sàrl | Process for the Preparation of Treprostinil and Derivatives Thereof |
KR102143961B1 (ko) | 2012-08-01 | 2020-08-12 | 유나이티드 세러퓨틱스 코오포레이션 | 프로스타시클린-처리된 내피 전구 세포를 사용한 폐동맥 고혈압의 치료 |
EP2879682B1 (en) | 2012-08-01 | 2018-03-21 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension with mesenchymal stem cells |
CA2890219A1 (en) | 2012-11-30 | 2014-06-05 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
ES2697573T3 (es) | 2013-01-09 | 2019-01-25 | United Therapeutics Corp | Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas |
US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
ES2927844T3 (es) * | 2013-01-11 | 2022-11-11 | Corsair Pharma Inc | Profármacos de treprostinil |
CA3212313A1 (en) | 2013-03-14 | 2014-10-02 | United Therapeutics Corporation | Solid forms of treprostinil |
EP2970081A4 (en) | 2013-03-15 | 2016-10-12 | United Therapeutics Corp | SALTS OF TREPROSTINIL |
WO2014160638A1 (en) | 2013-03-25 | 2014-10-02 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
CA2911172C (en) | 2013-04-30 | 2021-10-19 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
WO2014203278A2 (en) | 2013-06-19 | 2014-12-24 | Msn Laboratories Private Limited | NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID |
US9925184B2 (en) | 2013-10-11 | 2018-03-27 | Pulmokine, Inc. | Spray-dry formulations |
EA031604B1 (ru) * | 2013-10-25 | 2019-01-31 | Инсмед Инкорпорейтед | Трепростинильные соединения, композиции и способы их использования |
WO2015138423A1 (en) | 2014-03-11 | 2015-09-17 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
US20170095432A1 (en) | 2014-06-13 | 2017-04-06 | United Therapeutics Corporation | Treprostinil formulations |
CA2964804C (en) | 2014-10-20 | 2019-04-02 | United Therapeutics Corporation | Synthesis of intermediate for producing prostacyclin derivatives |
CA2967385C (en) | 2014-11-18 | 2023-05-16 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
WO2016176555A1 (en) | 2015-04-29 | 2016-11-03 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
AU2017261317A1 (en) | 2016-05-05 | 2018-12-13 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
WO2017223400A1 (en) | 2016-06-24 | 2017-12-28 | Insmed Incorporated | Prostacyclin compounds and compositions for treating sarcoidosis |
CA3038276A1 (en) | 2016-09-26 | 2018-03-29 | United Therapeutics Corporation | Treprostinil prodrugs |
EP3673895A1 (en) | 2018-12-28 | 2020-07-01 | Université Libre de Bruxelles | Dry powder inhalation formulation and its use for the therapeutic treatment of lungs |
KR20220002600A (ko) | 2019-04-29 | 2022-01-06 | 인스메드 인코포레이티드 | 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법 |
-
2015
- 2015-11-18 CA CA2967385A patent/CA2967385C/en active Active
- 2015-11-18 JP JP2017526523A patent/JP6866043B2/ja active Active
- 2015-11-18 EP EP15862092.2A patent/EP3221291B1/en active Active
- 2015-11-18 US US15/527,811 patent/US10343979B2/en active Active
- 2015-11-18 ES ES15862092T patent/ES2873873T3/es active Active
- 2015-11-18 AU AU2015349969A patent/AU2015349969B2/en active Active
- 2015-11-18 WO PCT/US2015/061427 patent/WO2016081658A1/en active Application Filing
- 2015-11-18 EP EP21164646.8A patent/EP3904326A1/en not_active Withdrawn
-
2018
- 2018-03-26 HK HK18104145.6A patent/HK1244783A1/zh unknown
-
2019
- 2019-05-21 US US16/417,958 patent/US11148997B2/en active Active
-
2021
- 2021-09-09 US US17/470,723 patent/US20220135513A1/en not_active Abandoned
-
2023
- 2023-04-18 US US18/302,682 patent/US20230250051A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017535555A5 (ja) | ||
JP2017511305A5 (ja) | ||
JP2008523069A5 (ja) | ||
JP2017061563A5 (ja) | ||
TWI645901B (zh) | 雙環烷基化合物及合成 | |
EA201070874A1 (ru) | Производные индол-2-карбоксамидов и азаиндол-2-карбоксамидов, замещённых силанильной группой, их получение и применение в терапии | |
JP5735659B2 (ja) | シタグリプチンの中間体の製造方法 | |
JP2013518962A5 (ja) | ||
JP2012508235A5 (ja) | ||
JP2014015483A5 (ja) | ||
JP2010512316A5 (ja) | ||
JP2015518473A5 (ja) | ||
RU2020105524A (ru) | Алкоксилированные сложные эфирамины и их соли | |
DE602006008962D1 (de) | Verfahren zur herstellung von valsartan | |
RU2011115572A (ru) | Группа аминозамещенных бензоилпроизводных, их получение и применение | |
RU2013119617A (ru) | Способ получения 2-амино-n-(2, 2, 2-трифторэтил)ацетамида | |
JP2012531508A5 (ja) | ||
JP2011524871A5 (ja) | ||
ES2320323T3 (es) | Procedimiento para la preparacion de poliamidas ciclicas con proteccion n-1 que contienen atomos de nitrogeno en forma de anillo n, y producto asi obtenido. | |
JP2018502174A5 (ja) | ||
JP2010529044A5 (ja) | ||
RU2011118583A (ru) | 5-о-производные авермектина, способ их получения и антипаразитарные средства на их основе | |
JP2017513885A5 (ja) | ||
PE20090824A1 (es) | Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas | |
JP2015508069A5 (ja) |